FDG PET/CT Scan for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
Is the FDG PET/CT scan safe for humans?
How does the FDG PET/CT scan treatment for glioblastoma differ from other treatments?
The FDG PET/CT scan is unique because it combines imaging techniques to noninvasively assess the metabolic activity of brain tumors, helping to identify the most aggressive parts of glioblastoma. This approach allows for more precise treatment planning compared to traditional methods, which may not provide as detailed a view of tumor metabolism and activity.35678
What data supports the effectiveness of the treatment Fludeoxyglucose F-18, 18F-FDG, Fludeoxyglucose F-18, FDG for glioblastoma?
FDG-PET scans, which use Fludeoxyglucose F-18, are helpful in managing brain tumors like glioblastoma by showing how the tumor uses glucose, which can help doctors make treatment decisions. They are particularly useful for distinguishing between tumor regrowth and tissue damage from radiation, and for monitoring how well a treatment is working.29101112
Who Is on the Research Team?
Johannes Czernin, MD
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients with high-grade glioma, specifically glioblastoma, who are about to start therapy. They must be able to provide written consent and not have severe psychiatric illnesses. Pregnant or breastfeeding individuals cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients undergo chemotherapy and FDG PET/CT scans to monitor very early therapy response
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Fludeoxyglucose F-18
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jonsson Comprehensive Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
National Institutes of Health (NIH)
Collaborator